Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04594187 · ClinicalTrials.gov registry record · Phase 2
Nodal Radiation Therapy for Sentinel Lymph Node Positive Melanoma
A Phase 2 study of Melanoma, sponsored by M.D. Anderson Cancer Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 168
- Enrollment target
- 3
- Study locations
NCT04594187 is a Phase 2 study of Melanoma that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 168 participants, below the 706-participant average among 266 other Melanoma trials with a reported enrollment target (76% lower). The trial reports 3 study locations across 3 states.
The verdict
NCT04594187, a Phase 2 study of Melanoma, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 168 participants
- Enrollment target
- 3
- Study locations
Study Summary
This phase II trial seeks to determine the role of nodal radiation therapy after sentinel lymph node biopsy (SLNB) for patients with high risk sentinel lymph node positive melanoma who are planned for immunotherapy without completion lymph node dissection. Prior studies of patients with more advanced melanoma have shown nodal radiation therapy can decrease the risk of nodal recurrence but it is not known if this same benefit will be seen in patients with high risk sentinel lymph node positive disease who are planned for immunotherapy.
Conditions Studied
Interventions
- OTHER Quality-of-Life Assessment
- RADIATION Radiation Therapy
- OTHER Immunotherapy
Study Locations (3)
Florida
- Baptist - MD Anderson Cancer Center - Jacksonville
New Jersey
- Cooper Hospital UNIV MED CTR. - Camden
Texas
- M D Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 168 participants |
| Start Date | 2021-08-26 |
| Est. Completion | 2027-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04594187
The ClinicalTrials.gov registry entry for NCT04594187 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 168 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 706-participant average among 266 other Melanoma trials with a reported enrollment target (76% lower). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Melanoma appearing as the primary indexed condition, and to 3 interventions - of which Quality-of-Life Assessment is the first listed.
NCT04594187 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Florida, New Jersey, Texas.
Frequently Asked Questions
What is clinical trial NCT04594187 about?
NCT04594187 is a clinical study titled "Nodal Radiation Therapy for Sentinel Lymph Node Positive Melanoma". This phase II trial seeks to determine the role of nodal radiation therapy after sentinel lymph node biopsy (SLNB) for patients with high risk sentinel lymph node positive melanoma who are planned for immunotherapy without completion lymph node dissection. Prior studies of patients with more advance...
What is the current status of trial NCT04594187?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 168 participants. The study started on 2021-08-26. Estimated completion is 2027-12-31.
What conditions does trial NCT04594187 study?
This clinical trial studies the following conditions: Melanoma.
What interventions are being tested in trial NCT04594187?
The interventions under investigation include: Quality-of-Life Assessment (OTHER), Radiation Therapy (RADIATION), Immunotherapy (OTHER).
Who is sponsoring clinical trial NCT04594187?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04594187 being conducted?
This trial has 3 study locations across Florida, New Jersey, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies
RECRUITING · Phase 2
-
Neoadjuvant Immune Checkpoint Blockade + a Prebiotic Food-enriched Dietary Intervention to Optimize Immune Response in Melanoma: NEO-PreFED
RECRUITING · Phase 2
-
Zimberelimab (AB122) With TIGIT Inhibitor Domvanalimab (AB154) in PD-1 Relapsed/Refractory Melanoma
RECRUITING · Phase 2
-
A Study of IBI363 in Subjects with Advanced Solid Malignancies
RECRUITING · Phase 2
-
A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab
RECRUITING · Phase 2
-
Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.